10-K/A: 2seventy bio Files Amendment to 2024 Annual Report on Form 10-K
Form 10-K/A Amendment
2seventy bio files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
Summary
- 2seventy bio, Inc. filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The amendment includes information previously omitted from Part III of the original report, specifically Items 10 through 14, and Part IV, Item 15.
- The filing also includes new certifications by the company's principal executive officer and principal financial officer.
- The amendment does not modify or update disclosures in the original report or reflect events occurring after March 25, 2025.
- The company's common stock is traded on the Nasdaq Stock Market LLC under the ticker symbol TSVT.
- As of April 23, 2025, there were 53,228,315 shares of the company's common stock outstanding.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It provides necessary information but doesn't convey strong positive or negative signals.
Positives
- The company has a Compensation Recovery Policy in place.
- The company has adopted an insider trading policy.
- The company has a non-employee director compensation policy in place to attract and retain qualified directors.
- The Board is composed of a majority of independent directors.
Risks
- The company faces risks related to the development and commercialization of Abecma.
- Risks exist related to manufacturing and supply chain, regulatory reviews and approvals, and intellectual property.
- The company faces risks related to strategic alliances, competition, litigation, government investigations, and cybersecurity.
Future Outlook
The document does not provide a specific future outlook beyond the information required in the amendment.
Industry Context
This announcement is a standard regulatory filing update and doesn't provide specific insights into broader industry trends beyond the company's operations within the biotechnology and pharmaceutical sectors.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Nick Leschly | William D. Baird, III | 2024-04-01 | Transition to Chair of the Board |
| Chair of the Board | Nick Leschly | 2024-04-01 | Transition from CEO | |
| Chief Financial Officer | Victoria Eatwell | 2024-04-01 | Promotion from Senior Vice President of Finance | |
| Chief Operating Officer | Jessica Snow | 2025-01-06 | Promotion from SVP of Quality & Head of Operations |
Key Dates
| Date | Description |
|---|---|
| 2010-09 | Nick Leschly served as bluebird bio's chief executive officer since September 2010. |
| 2011 | Eli Casdin founded Casdin Capital in 2011. |
| 2012-04 | William D. Baird served as Chief Financial Officer of Amicus Therapeutics, Inc. from April 2012 until February 2019. |
| 2015-04 | Victoria Eatwell joined bluebird bio in April 2015. |
| 2017 | Denice Torres founded The Ignited Company in 2017. |
| 2019-02 | William D. Baird served as bluebird bio's Chief Financial Officer from February 2019. |
| 2021-04-01 | On April 1, 2024, Mr. Leschly transitioned from 2seventy bios Chief Executive Officer to named Chair of the Board. |
| 2021-05-04 | Nick Leschly has been a member of our Board of Directors (the Board) since May 4, 2021. |
| 2021-10-15 | Sarah Glickman has served as a member of our Board and the chair of the audit committee of the Board since October 15, 2021. |
| 2021-11 | William D. Baird served as our Chief Financial Officer since the separation from bluebird bio in November 2021. |
| 2023-03-08 | Wei Lin, M.D. has served as a member of our Board since March 8, 2023. |
| 2023-09 | William D. Baird served as our Chief Operating Officer from September 2023 to April 2024. |
| 2024-01-29 | The Company entered into an asset purchase agreement (the Asset Purchase Agreement) with Regeneron Pharmaceuticals, Inc. on January 29, 2024 for the sale of the Companys oncology and autoimmune research and development programs, clinical manufacturing capabilities, and related platform technologies to Regeneron. |
| 2024-03 | Charles Newton has served as a member of our Board since March 2024. |
| 2024-04-01 | Effective as of the Asset Sale Closing, Mr. Baird was appointed as our Chief Executive Officer and Mr. Leschly transitioned to Chair of our Board. |
| 2024-04-01 | Effective as of the Asset Sale Closing, Ms. Eatwell was appointed as our Chief Financial Officer and Ms. Snow was appointed as our Senior Vice President of Quality and Enabling Functions. |
| 2025-01-06 | Ms. Snow was appointed as our Chief Operating Officer effective January 6, 2025. |
| 2025-03-10 | Agreement and Plan of Merger, dated as of March 10, 2025, by and among Bristol-Myers Squibb Company, Daybreak Merger Sub Inc. and 2seventy bio, Inc. |
| 2025-04-01 | As of April 1, 2025, we had 52,470,757 shares of common stock outstanding. |
| 2025-04-23 | The number of shares of registrants common stock outstanding as of April 23, 2025, was 53,228,315. |
| 2025-04-28 | Age of directors and executive officers as of April 28, 2025. |
Keywords
executive compensation, corporate governance, directors, executive officers, amendment, Form 10-K, 2seventy bio
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.